Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients
Open Access
- 9 December 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in Supportive Care in Cancer
- Vol. 20 (4), 877-881
- https://doi.org/10.1007/s00520-011-1336-0
Abstract
To investigate the impact of chemotherapy-induced neurotoxicity on daily activities and quality of life (QoL) of cancer patients. QoL of all patients visiting the oncological outpatient ward of the Maxima Medical Centre in the Netherlands from October 2006 until March 2007 treated with taxanes, vinca-alkaloids and/or platinum compounds (n = 88) was compared with the QoL of patients that did not receive these treatments yet (n = 43). Patient-reported neuropathy symptoms were evaluated with the newly developed Chemotherapy Induced Neurotoxicity Questionnaire (CINQ) and the Functional Assessment of Cancer Therapy/Gynaecologic Oncology Group/Neurotoxicity (FACT/GOG-Ntx) questionnaire. Patients treated with chemotherapy reported significantly more complaints of neuropathy (p < 0.001) and more paresthesias and dysesthesias in the upper (p < 0.001; p < 0.01) and lower extremities (p < 0.001) compared to those not treated with chemotherapy. They additionally experienced problems with fine motor function (e.g., getting (un)dressed, writing, and picking up small objects). Moreover, cold-induced paresthesias were frequently reported. Overall, patients indicated that their neuropathy had a negative effect on QoL. The newly developed CINQ and the FACT/GOG-Ntx results suggest a considerable negative impact of patient-reported neuropathy symptoms on daily activities and QoL in cancer patients treated with chemotherapy. However, further validation of the CINQ is needed.This publication has 18 references indexed in Scilit:
- Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group studyInternational Journal of Gynecologic Cancer, 2007
- Prevention of Oxaliplatin-Related Neurotoxicity by Calcium and Magnesium InfusionsClinical Cancer Research, 2004
- Psychometric Evaluation of Two Scales Assessing Functional Status and Peripheral Neuropathy Associated With Chemotherapy for Ovarian Cancer: A Gynecologic Oncology Group StudyOncology Nursing Forum, 2004
- Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapyInternational Journal of Gynecologic Cancer, 2003
- Comparative neurotoxicity of weekly non-break paclitaxel infusions over 1 versus 3 hAnti-Cancer Drugs, 2003
- Protection against oxaliplatin acute neurosensory toxicity by venlafaxineAnti-Cancer Drugs, 2003
- Neurotoxic Complications of Chemotherapy in Patients with CancerDrugs, 2003
- Chemotherapy-Induced Peripheral NeuropathyCancer Investigation, 2003
- Clinical aspects and molecular basis of oxaliplatin neurotoxicity: Current management and development of preventive measuresSeminars in Oncology, 2002
- Chemotherapy-associated neurotoxicity: an important side effect-impacting on quality, rather than quantity, of lifeZeitschrift für Krebsforschung und Klinische Onkologie, 1996